ANN ARBOR STAGE IV GRADE 3 FOLLICULAR LYMPHOMA
Clinical trials for ANN ARBOR STAGE IV GRADE 3 FOLLICULAR LYMPHOMA explained in plain language.
Never miss a new study
Get alerted when new ANN ARBOR STAGE IV GRADE 3 FOLLICULAR LYMPHOMA trials appear
Sign up with your email to follow new studies for ANN ARBOR STAGE IV GRADE 3 FOLLICULAR LYMPHOMA, keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.
By submitting, you agree to our Terms of use
-
New drug cocktail shows promise for controlling common lymphoma
Disease control OngoingThis study tests a combination of three drugs (acalabrutinib, lenalidomide, and rituximab) in 60 people with untreated stage III-IV follicular lymphoma. The goal is to see how well these drugs work together to shrink or control the cancer. Participants must have a specific type o…
Matched conditions: ANN ARBOR STAGE IV GRADE 3 FOLLICULAR LYMPHOMA
Phase: PHASE2 • Sponsor: M.D. Anderson Cancer Center • Aim: Disease control
Last updated May 17, 2026 11:20 UTC
-
New drug cocktail shows promise for common blood cancer
Disease control OngoingThis early-phase study tested a combination of three drugs (rituximab, lenalidomide, and ibrutinib) in 33 people with untreated follicular lymphoma, a slow-growing blood cancer. The goal was to find the safest doses and see how well the drugs work together. While the treatment ai…
Matched conditions: ANN ARBOR STAGE IV GRADE 3 FOLLICULAR LYMPHOMA
Phase: PHASE1 • Sponsor: National Cancer Institute (NCI) • Aim: Disease control
Last updated May 17, 2026 11:19 UTC
-
New combo therapy shows promise for Hard-to-Treat lymphoma
Disease control OngoingThis study tests a new drug called ALX148 combined with two standard treatments (rituximab and lenalidomide) for people with B-cell non-Hodgkin lymphoma that has not responded to prior therapy. The goal is to find the best dose and see if the combination can shrink or control the…
Matched conditions: ANN ARBOR STAGE IV GRADE 3 FOLLICULAR LYMPHOMA
Phase: PHASE1, PHASE2 • Sponsor: M.D. Anderson Cancer Center • Aim: Disease control
Last updated May 08, 2026 12:00 UTC